Long-Term Extension Trial of Tildrakizumab to Prove Its S... | NCT03552276

Label	Type	Description	Intervention Names
SUNPG18_07 q4 weeks, high dose	Experimental	Tildrakizumab 200 mg q4 Weeks	Drug: SUNPG18_07 I (Tildrakizumab 200 mg)
SUNPG18_07 q12 weeks, high dose	Experimental	Tildrakizumab 200 mg q12 Weeks	Drug: SUNPG18_07 I (Tildrakizumab 200 mg)
SUNPG18_07 q12 weeks, low dose	Experimental	Tildrakizumab 100 mg q12 Weeks	Drug: SUNPG18_07 II (Tildrakizumab 100 mg)
SUNPG18_07 q4 Weeks, High Dose to SUNPG18_07 q12 Weeks, Low Dose	Experimental	Tildrakizumab 200 mg q4 weeks switched to tildrakizumab 100 mg q12 weeks	Drug: SUNPG18_07 I (Tildrakizumab 200 mg) Drug: SUNPG18_07 II (Tildrakizumab 100 mg)
SUNPG18_07 q12 Weeks, High Dose to SUNPG18_07 q12 Weeks, Low Dose	Experimental	Tildrakizumab 200 mg q12 weeks switched to tildrakizumab 100 mg q12 weeks	Drug: SUNPG18_07 I (Tildrakizumab 200 mg) Drug: SUNPG18_07 II (Tildrakizumab 100 mg)

Name	Type	Description	Arm Group Labels	Other Names
SUNPG18_07 I (Tildrakizumab 200 mg)	Drug	injection	SUNPG18_07 q12 Weeks, High Dose to SUNPG18_07 q12 Weeks, Low Dose SUNPG18_07 q12 weeks, high dose

Measure	Description	Time Frame
Number of Participants With Adverse Events	Please refer to Adverse event section for more information	upto week 208

Facility	Status	City	State	ZIP	Country	Contacts
Site 25		Glendale	Arizona	85306	United States
Site 16

ID	Title	Description
FG000	Tildrakizumab 200 mg q4 Weeks	The subjects in this group entered the LTE study from the parent study, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
FG001	Tildrakizumab 200 mg q12 Weeks

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Jul 22, 2020	Sep 17, 2024

Other Adverse Events

Term	Organ System	Assessment Type	Statistical Information
Anaemia	Blood and lymphatic system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG0030 affected54 at risk EG0043 affected151 at risk
Leukocytosis	Blood and lymphatic system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Leukopenia	Blood and lymphatic system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Lymphadenopathy	Blood and lymphatic system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Lymphopenia	Blood and lymphatic system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Neutropenia	Blood and lymphatic system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Neutrophilia	Blood and lymphatic system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Acute myocardial infarction	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Atrial fibrillation	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Atrioventricular block first degree	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Cardiac failure	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Cardiac failure congestive	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Coronary artery stenosis	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Diastolic dysfunction	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Mitral valve incompetence	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Myocardial ischaemia	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Palpitations	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Pericardial cyst	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Sinus tachycardia	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Tachycardia	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Tricuspid valve incompetence	Cardiac disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Accessory spleen	Congenital, familial and genetic disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Gilbert's syndrome	Congenital, familial and genetic disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hydrocele	Congenital, familial and genetic disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Ear pain	Ear and labyrinth disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Vertigo	Ear and labyrinth disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Autoimmune thyroiditis	Endocrine disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Goitre	Endocrine disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Hypothyroidic goitre	Endocrine disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hypothyroidism	Endocrine disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Thyroid mass	Endocrine disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Astigmatism	Eye disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Blepharitis	Eye disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Blindness transient	Eye disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Cataract	Eye disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Cataract nuclear	Eye disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Diabetic retinopathy	Eye disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Keratitis	Eye disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Myopia	Eye disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Retinal vascular disorder	Eye disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Visual acuity reduced	Eye disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Abdominal hernia	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Abdominal pain	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0024 affected49 at risk EG003
Abdominal pain upper	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Abdominal rigidity	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Anal fistula	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Aphthous ulcer	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Barrett's oesophagus	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Chronic gastritis	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Coeliac artery stenosis	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Constipation	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Dental caries	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0023 affected49 at risk EG003
Diaphragmatic hernia	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Diarrhoea	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0014 affected22 at risk EG0023 affected49 at risk EG003
Diverticulum	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Diverticulum intestinal	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Duodenitis	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Dyspepsia	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Enteritis	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Food poisoning	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Gastric ulcer	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Gastritis	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Gastritis erosive	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Gastrointestinal disorder	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Gastrooesophageal reflux disease	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Gingival swelling	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Haemorrhagic erosive gastritis	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Haemorrhoids	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hiatus hernia	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Intestinal metaplasia	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Intestinal obstruction	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Irritable bowel syndrome	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Large intestine polyp	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0022 affected49 at risk EG003
Nausea	Gastrointestinal disorders	Systematic Assessment	EG0001 affected5 at risk EG0012 affected22 at risk EG0022 affected49 at risk EG003
Pancreatitis chronic	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Rectal polyp	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Retained deciduous tooth	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Toothache	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Vomiting	Gastrointestinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0022 affected49 at risk EG003
Asthenia	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Chest pain	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Chills	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Drug intolerance	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Fatigue	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0021 affected49 at risk EG003
Generalised oedema	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Influenza like illness	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0022 affected49 at risk EG003
Injection site erythema	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Injection site pain	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Injection site pruritus	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Injection site rash	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Injection site reaction	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Injury associated with device	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Oedema peripheral	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Pyrexia	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0023 affected49 at risk EG003
Vaccination site pain	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Xerosis	General disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Biliary dyskinesia	Hepatobiliary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Cholecystitis	Hepatobiliary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Cholelithiasis	Hepatobiliary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Cholestasis	Hepatobiliary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Diabetic hepatopathy	Hepatobiliary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Gallbladder polyp	Hepatobiliary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hepatic steatosis	Hepatobiliary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Hepatitis	Hepatobiliary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Hyperbilirubinaemia	Hepatobiliary disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0021 affected49 at risk EG003
Hypertransaminasaemia	Hepatobiliary disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Non-alcoholic steatohepatitis	Hepatobiliary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Steatohepatitis	Hepatobiliary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Allergy to arthropod bite	Immune system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Allergy to plants	Immune system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Abdominal abscess	Infections and infestations	Systematic Assessment	EG0001 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Acute sinusitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Adenovirus infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Bacteriuria	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Bartholin's abscess	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Breast abscess	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Bronchitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0012 affected22 at risk EG0021 affected49 at risk EG003
COVID-19	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0023 affected49 at risk EG003
COVID-19 pneumonia	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Cellulitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Chronic sinusitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Conjunctivitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Coronavirus infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Cystitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Diverticulitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Erythema migrans	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Escherichia infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Furuncle	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Gallbladder empyema	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Gastroenteritis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Gastroenteritis viral	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Gastrointestinal bacterial overgrowth	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Gastrointestinal infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Gingivitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Helicobacter gastritis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Helicobacter infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Herpes simplex	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Herpes zoster	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hordeolum	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Influenza	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0021 affected49 at risk EG003
Intestinal sepsis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Joint abscess	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Laryngitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Localised infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Lower respiratory tract infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Nasopharyngitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0027 affected49 at risk EG003
Oral herpes	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Otitis externa	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Otitis media	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Periodontitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Pharyngitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Pharyngotonsillitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Pneumonia	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Pneumonia bacterial	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Pulmonary tuberculosis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Pulpitis dental	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Purulent discharge	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Pyelonephritis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Pyelonephritis acute	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Respiratory tract infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Respiratory tract infection viral	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0023 affected49 at risk EG003
Rhinitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Septic shock	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Sinusitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0012 affected22 at risk EG0020 affected49 at risk EG003
Skin infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Suspected COVID-19	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Tonsillitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Tooth infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Tracheitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Tracheobronchitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Upper respiratory tract infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0027 affected49 at risk EG003
Urinary tract infection	Infections and infestations	Systematic Assessment	EG0001 affected5 at risk EG0011 affected22 at risk EG0022 affected49 at risk EG003
Vaginal infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Viral infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Viral pharyngitis	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Viral upper respiratory tract infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Vulvovaginal mycotic infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Wound infection	Infections and infestations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Burns second degree	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Concussion	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Contusion	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0021 affected49 at risk EG003
Craniocerebral injury	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Cuboid syndrome	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Epicondylitis	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Fall	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0012 affected22 at risk EG0021 affected49 at risk EG003
Fibula fracture	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Foot fracture	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hand fracture	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hip fracture	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Humerus fracture	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Iliotibial band syndrome	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Immunisation reaction	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Joint injury	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Ligament rupture	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Ligament sprain	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Limb injury	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Meniscus injury	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Muscle strain	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Nail avulsion	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Post vaccination syndrome	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Skin abrasion	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Skin laceration	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Soft tissue injury	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Spinal compression fracture	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Subdural haematoma	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Synovial rupture	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Tendon injury	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Thermal burn	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Tibia fracture	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Tooth fracture	Injury, poisoning and procedural complications	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Alanine aminotransferase increased	Investigations	Systematic Assessment	EG0001 affected5 at risk EG0010 affected22 at risk EG0022 affected49 at risk EG003
Apolipoprotein B increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Aspartate aminotransferase increased	Investigations	Systematic Assessment	EG0001 affected5 at risk EG0011 affected22 at risk EG0022 affected49 at risk EG003
Bilirubin conjugated increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Bilirubin urine present	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Biopsy kidney	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Blood bilirubin increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0021 affected49 at risk EG003
Blood cholesterol increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Blood creatine phosphokinase increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0022 affected49 at risk EG003
Blood creatinine increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Blood glucose increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0022 affected49 at risk EG003
Blood pressure increased	Investigations	Systematic Assessment	EG0001 affected5 at risk EG0010 affected22 at risk EG0023 affected49 at risk EG003
Blood triglycerides increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Blood urea increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
C-reactive protein increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Gamma-glutamyltransferase increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0021 affected49 at risk EG003
Glomerular filtration rate decreased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Haematocrit decreased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Haemoglobin decreased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Hepatic enzyme increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Low density lipoprotein increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Lymphocyte count decreased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Monocyte count decreased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Neutrophil count decreased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Platelet count decreased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Prostatic specific antigen increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Red blood cell count decreased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Transaminases increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Urinary casts	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Weight decreased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Weight increased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
White blood cell count decreased	Investigations	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Cholesterosis	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Copper deficiency	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Dehydration	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0022 affected49 at risk EG003
Diabetes mellitus	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0022 affected49 at risk EG003
Diabetes mellitus inadequate control	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Dyslipidaemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Glucose tolerance impaired	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hypercholesterolaemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0012 affected22 at risk EG0021 affected49 at risk EG003
Hyperglycaemia	Metabolism and nutrition disorders	Systematic Assessment	EG0001 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Hyperlipidaemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Hypertriglyceridaemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hyperuricaemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Hypokalaemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hypomagnesaemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hyponatraemia	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Impaired fasting glucose	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Insulin resistance	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Obesity	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Type 2 diabetes mellitus	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Vitamin D deficiency	Metabolism and nutrition disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Arthralgia	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0013 affected22 at risk EG0021 affected49 at risk EG003
Arthritis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0012 affected22 at risk EG0021 affected49 at risk EG003
Back pain	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0024 affected49 at risk EG003
Bursitis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Dactylitis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Exostosis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Fracture pain	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Greater trochanteric pain syndrome	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Intervertebral disc disorder	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Intervertebral disc displacement	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Intervertebral disc protrusion	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Jaw cyst	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Joint contracture	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Joint effusion	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Joint swelling	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Lumbar spinal stenosis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Metatarsalgia	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Muscle spasms	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Musculoskeletal discomfort	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Musculoskeletal stiffness	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Myalgia	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0022 affected49 at risk EG003
Neck pain	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Osteoarthritis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0022 affected49 at risk EG003
Osteochondrosis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Osteoporosis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Pain in extremity	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0012 affected22 at risk EG0020 affected49 at risk EG003
Periarthritis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Periarticular disorder	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Plantar fasciitis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Pseudarthrosis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Psoriatic arthropathy	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0012 affected22 at risk EG0021 affected49 at risk EG003
Rhabdomyolysis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Rotator cuff syndrome	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Sacroiliitis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Spinal disorder	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Spinal osteoarthritis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Spinal pain	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Spinal stenosis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Spondylolisthesis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Synovial cyst	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Tendonitis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0012 affected22 at risk EG0022 affected49 at risk EG003
Tenosynovitis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Tenosynovitis stenosans	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Trigger finger	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Adenocarcinoma metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Adrenal adenoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Anogenital warts	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Benign oesophageal neoplasm	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Colorectal adenoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Haemangioma of liver	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Invasive ductal breast carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Oesophageal carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Prostatic adenoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Uterine leiomyoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Anosmia	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Bradykinesia	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Carpal tunnel syndrome	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Cervicobrachial syndrome	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Diabetic neuropathy	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Dizziness	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Encephalopathy	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Headache	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0023 affected49 at risk EG003
Hypoaesthesia	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Lumbar radiculopathy	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Lumbosacral radiculopathy	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Metabolic encephalopathy	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Migraine	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Myotonia	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Neuralgia	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Neuritis	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Parkinson's disease	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Restless legs syndrome	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0022 affected49 at risk EG003
Retinal migraine	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Sciatica	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Sensory loss	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Spinal cord haematoma	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Subarachnoid haemorrhage	Nervous system disorders	Systematic Assessment	EG0001 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Syncope	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Tension headache	Nervous system disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Adjustment disorder	Psychiatric disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Affective disorder	Psychiatric disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Anxiety	Psychiatric disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0022 affected49 at risk EG003
Depression	Psychiatric disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Insomnia	Psychiatric disorders	Systematic Assessment	EG0000 affected5 at risk EG0012 affected22 at risk EG0020 affected49 at risk EG003
Irritability	Psychiatric disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Mixed anxiety and depressive disorder	Psychiatric disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Sleep disorder	Psychiatric disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Stress	Psychiatric disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Acute kidney injury	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Calculus urinary	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Chronic kidney disease	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Cystitis haemorrhagic	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Cystitis noninfective	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
End stage renal disease	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Glomerulonephritis chronic	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Haematuria	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hypertonic bladder	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Nephrolithiasis	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Nephrosclerosis	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Pollakiuria	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Proteinuria	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Renal colic	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Renal cyst	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Stress urinary incontinence	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Ureterolithiasis	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Urinary tract inflammation	Renal and urinary disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Abnormal uterine bleeding	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Adenomyosis	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Bartholin's cyst	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Erectile dysfunction	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Hydrocele female	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Intermenstrual bleeding	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Menstruation irregular	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Prostatitis	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Prostatomegaly	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Uterine haemorrhage	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Vaginal discharge	Reproductive system and breast disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Bronchitis chronic	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Dysphonia	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Interstitial lung disease	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Nasal congestion	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Respiratory failure	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Sinus congestion	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Sleep apnoea syndrome	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Upper respiratory tract inflammation	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Alopecia	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Angioedema	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Dermatitis allergic	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Dermatitis contact	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Dermatitis psoriasiform	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Ecchymosis	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Erythema	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hidradenitis	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Pruritus	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Psoriasis	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Rash	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0012 affected22 at risk EG0020 affected49 at risk EG003
Skin exfoliation	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Skin ulcer	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Gastric bypass	Surgical and medical procedures	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Aortic arteriosclerosis	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Aortic dissection	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0011 affected22 at risk EG0020 affected49 at risk EG003
Arteriosclerosis	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Bleeding varicose vein	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Blood pressure fluctuation	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Deep vein thrombosis	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Diabetic microangiopathy	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Essential hypertension	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Hypertension	Vascular disorders	Systematic Assessment	EG0002 affected5 at risk EG0010 affected22 at risk EG0022 affected49 at risk EG003
Hypertensive crisis	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0021 affected49 at risk EG003
Lymphostasis	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Peripheral venous disease	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Phlebitis	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003
Thrombophlebitis	Vascular disorders	Systematic Assessment	EG0000 affected5 at risk EG0010 affected22 at risk EG0020 affected49 at risk EG003

ID	Title	Description
BG000	Tildrakizumab q4 Weeks, 200 mg	The subjects in this group entered the LTE study from the parent study, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
BG001	Tildrakizumab 200 mg q12 Weeks	The subjects in this group entered the LTE study from the parent study, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
BG002	Tildrakizumab 100 mg q12 Weeks	These subjects continued to receive same dose of tildrakizumab 100 mg q12 weeks in the LTE study as in the parent study. However, in the LTE study, post DBL of the parent study, the dose was open label.
BG003	Tildrakizumab 200 mg q4 Weeks Switched to Tildrakizumab 100 mg q12 Weeks	This group represents subjects who switched from tildrakizumab 200 mg q4 weeks dose to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study.
BG004	Tildrakizumab 200 mg q12 Weeks Switched to Tildrakizumab 100 mg q12 Weeks	This group represents subjects who switched from tildrakizumab 200 mg q12 weeks dose to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study
BG005	Total	Total of all reporting groups

ID	Term
D025242	Spondylarthropathies
D025241	Spondylarthritis
D013166	Spondylitis
D013122	Spinal Diseases
D001847	Bone Diseases
D009140	Musculoskeletal Diseases
D001168	Arthritis
D007592	Joint Diseases
D011565	Psoriasis
D017444	Skin Diseases, Papulosquamous
D012871	Skin Diseases
D017437	Skin and Connective Tissue Diseases

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Tildrakizumab 200 mg, q4 Weeks	The subjects in this group entered the LTE, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.	0	5	3	5	5	5
EG001	Tildrakizumab 200 mg, q12 Weeks	The subjects in this group entered the LTE study, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.	1	22	2	22	14	22
EG002	Tildrakizumab 100 mg q12 Weeks	These subjects continued to receive same dose of tildrakizumab 100 mg q12 weeks in the LTE study as in the parent study. However, in the LTE, post DBL of the parent study, the dose was open label.	0	49	7	49	36	49
EG003	Tildrakizumab 200 mg q4 Weeks, to Tildrakizumab 100 mg q12 Weeks	This group represents subjects who switched from tildrakizumab 200 mg q4 weeks to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study.	0	54	3	54	44	54
EG004	Tildrakizumab 200 mg q12 Weeks, to Tildrakizumab 100 mg q12 Weeks	This group represents subjects who switched from tildrakizumab 200 mg q4 weeks to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study	1	151	25	151	125	151